BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26907933)

  • 1. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.
    Stalmans I; Oddone F; Cordeiro MF; Hommer A; Montesano G; Ribeiro L; Sunaric-Mégevand G; Rossetti L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1151-8. PubMed ID: 26907933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
    Cucherat M; Stalmans I; Rouland JF
    J Glaucoma; 2014 Jan; 23(1):e69-75. PubMed ID: 23881267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
    DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial.
    Muñoz-Negrete FJ; Topouzis F; Oddone F; Nisslé S; Rokicki D; Januleviciene I; Harasymowycz P; Stalmans I
    J Glaucoma; 2024 Jun; 33(6):422-430. PubMed ID: 38506750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
    El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
    Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
    Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
    BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
    Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
    Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.